Login to Your Account



Oxagen Raises $26M to Boost Midstage Asthma Compound

By Nuala Moran


Wednesday, November 25, 2009
LONDON - The flood of new money into European biotechs continued as Oxagen Ltd. announced the completion of a £16 million (US$26.4 million) third-round funding, with new investor Novartis Venture Funds leading the round. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription